Compare RILYL & MDCXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
B. Riley Financial Inc. Depositary Shares each representing 1/1000th in a share of 7.375% Series B Cumulative Perpetual Preferred Stock par value $0.0001
| Metric | RILYL | MDCXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | 2056 | 12 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | RILYL | MDCXW |
|---|---|---|
| Price | $5.15 | $0.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 6.0K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $1.12 |
| 52 Week High | N/A | $1.34 |
| Indicator | RILYL | MDCXW |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 38.43 |
| Support Level | $4.73 | $0.93 |
| Resistance Level | $5.57 | $0.82 |
| Average True Range (ATR) | 0.49 | 0.04 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 58.16 | 0.02 |
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, E-Commerce, Communications segment, and Consumer products segment.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.